Skip to search formSkip to main contentSkip to account menu

[ LAB] SCH66336

Known as: SCH-66336, SCH66336, SCH 66336 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

lonafarnib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma
We conducted a phase I clinical trial of the combination of SCH 66336 with temozolomide administered on the standard 5-day dosing… 
2008
2008
SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth…
Signal transducer and activators of transcription 3 (STAT3) is an important transcription factor that is essential for lung… 
2006
2006
A phase I study of temozolomide (TMZ) and the farnesyltransferase inhibitor (FTI), lonafarnib (Sarazar, SCH66336) in recurrent glioblastoma.
1556 Background: Farnesylation is essential for the post-translational modification of several proteins that play a role in cell… 
2004
2004
In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
K-ras alterations have been reported in 20-30% of non-small cell lung cancer (NSCLC) and represent a suitable target for the… 
Review
2003
Review
2003
Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.
Farnesyl Protein Transferase as a target for therapeutic intervention is currently under investigation in human clinical trials… 
2003
2003
Overcoming resistance to imatinib by combining targeted agents.
Bcr-Abl, the causative molecular abnormality of CML [3][1] is known to activate numerous intracellular signaling proteins and… 
Review
2003
Review
2003
Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas.
Ras oncogenes (K-, H- and N-ras) are known to be involved in signal transduction pathways regulating cell growth and… 
2002
2002
Targeted therapy using novel agents in the treatment of non-small-cell lung cancer.
Patients with advanced non-small-cell lung cancer (NSCLC) have a poor prognosis and high mortality. The therapeutic improvement… 
2002
2002
Phase I-II study of a Farnesyl Transferase Inhibitor (FTI), SCH66336, in patients with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML).
2000
2000
Combination therapy with SCH58500 (p53 adenovirus) and cyclophosphamide in preclinical cancer models.
SCH58500 (ACN53) is a replication-deficient, recombinant adenovirus which expresses human p53 tumor suppressor. In preclinical… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)